Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Allergan plc Ordinary Shares (NYSE:AGN)’s Botox Gets FDA Approval For Third Indication

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 04:15pm CET

Allergan plc Ordinary Shares (NYSE:AGN)’s Botox has received the approval of the U.S. Food and Drug Administration for a third indication – improving the facial appearance of adults who have particular forehead lines. Other indications for which the FDA has given approval for Botox include the treatment of glabellar lines and crow’s feet. This now makes Botox the sole neurotoxin approved for use in treating three distinct facial areas.

The decision to approve Botox for a third indication came after two clinical trials where the effectiveness of the treatment was compared to a placebo within a period of 30 days. In the first trial the primary endpoint was met by 61% of participants.

Aesthetics market

According to the chief executive officer of Allergan, Brent Saunders, the FDA approval will give the pharmaceutical company yet another opportunity in the aesthetics market which in his own words is the world’s best market.

“It’s high-quality, it’s cash-pay, it’s global. We are just at the initial stages of market development in the U.S. and almost every market in the world. So we have very high conviction around the sustainability,” Saunders is quoted as saying in an earnings call earlier in the year.

In this year’s first half, Botox generated approximately $1.53 billion in sales. This was an improvement of 12.7% compared to a year ago and was largely driven by strong demand. Now approved for the treatment of forehead lines, sales should rise even higher.

Body contouring

To bolster Allergan’s lineup in the aesthetics market, the pharmaceutical giant earlier in the year indicated that it was acquiring Zeltiq, a body contouring firm, at a price of $2.47 billion. Earlier in the year Allergan got Rhofade, a new rosacea treatment, approved. Three months ago the treatment had notched a familiarity rate of 75% among practices.

Additionally Allergan is involved in the development of Botox as a solution or particular medical cases such as prevention of chronic migraines. In Allergan’s line-up of aesthetics treatments the one product that has not been performing well is Kybella, a chin fat-buster.

On Wednesday shares of Allergan Plc fell by 0.67% to close the day at $208.39.

The post Allergan plc Ordinary Shares (NYSE:AGN)’s Botox Gets FDA Approval For Third Indication appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
02/23ALLERGAN : An Application for the Trademark "PYLERA" Has Been Filed by Allergan
AQ
02/23ALLERGAN : FDA Acceptance of Medicines360's Filing for supplemental New Drug App..
AQ
02/22ALLERGAN : FDA Acceptance of Medicines360's Filing for supplemental New Drug App..
PR
02/20ALLERGAN : Presents Data at the 2018 American Academy of Dermatology Annual Meet..
AQ
02/17ALLERGAN : Presents Data at the 2018 American Academy of Dermatology (AAD) Annua..
PU
02/16ALLERGAN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
02/15ALLERGAN : An Application for the Trademark "REJUVECROSS" Has Been Filed by Alle..
AQ
02/15ALLERGAN : Trademark Application for "REJUVACROSS" Filed by Allergan
AQ
02/15ALLERGAN : Matthew M. Walsh Appointed Executive Vice President and Chief Financi..
AQ
02/14ALLERGAN : s Forest Labs pays 726m in dividend
AQ
More news
News from SeekingAlpha
07:04aTracking Mason Hawkins' Southeastern Asset Management Portfolio - Q4 2017 Upd.. 
02/24Patent Office Puts Allergan's Mohawk Deal Out Of Its Misery 
02/23Tracking Larry Robbins' Glenview Capital Management Portfolio - Q4 2017 Updat.. 
02/23Will Analysts Abandon Allergan On Esmya Headwinds? 
02/23Premarket analyst action - healthcare 
Financials ($)
Sales 2018 15 196 M
EBIT 2018 7 274 M
Net income 2018 -1 246 M
Debt 2018 22 990 M
Yield 2018 1,83%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,00x
EV / Sales 2019 4,66x
Capitalization 53 014 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 216 $
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Matthew M. Walsh Chief Financial Officer & Executive VP
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
James H. Bloem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-2.56%53 014
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
MERCK AND COMPANY-3.02%148 618